• Open Access

First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen


  • This study was approved by the Institutional Review Boards of Hokkaido University School of Medicine and Institute for Genetic Medicine, Hokkaido University (Hokkaido, Japan) and registered at UMIN Clinical Trials Registry (http://www.umin.ac.jp/ctr/index-j.htm) as UMIN000003489 (Cancer vaccine study with MAGE-A4/Survivin helper peptide). Informed consent for publication was obtained from the patient.

To whom correspondence should be addressed.
E-mail: tak24@igm.hokudai.ac.jp


A patient with pulmonary metastasis of colon cancer was treated with artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP) of MAGE-A4 cancer antigen. The patient was vaccinated with MAGE-A4-H/K-HELP combined with OK432 and Montanide ISA-51. There were no severe side-effects except for a skin reaction at the injection site. MAGE-A4-H/K-HELP induced MAGE-A4-specific Th1 and Tc1 immune responses and the production of MAGE-A4-specific complement-fixing IgG antibodies. Tumor growth and carcinoembryonic antigen tumor marker were significantly decreased in the final diagnosis. This is the first report that artificially synthesized MAGE-A4-H/K-HELP induces Th1-dependent cellular and humoral immune responses in a human cancer patient. (Cancer Sci 2012; 103: 150–153)